Introduction {#s1}
============

Protein-protein interactions can be categorized into the following four classes: domain-domain interactions, mutual fit interactions, induced fit interactions and linear motif-domain interactions [@pone.0038637-Diella1]. The binding site for linear motif-domain interactions is a short peptide of only a few (three to ten) residues that is called a "short linear motif" (SLiM) [@pone.0038637-Diella1]. Three characteristics differentiate SLiMs from globular domains. The first characteristic is the ability of SLiMs to encode a functional interaction interface in a short (three to ten residues) and often poorly conserved sequence. The short length of the motifs also makes them much more likely to arise/disappear spontaneously via mutations, which make them more evolutionarily labile (i.e. likely to appear *de novo* in unrelated protein sequences) [@pone.0038637-Diella1]. The second feature of SLiMs is that the richness of potential motif-domain interactions is higher than the domain-domain interactions within a given length of sequence. The third characteristic of SLiMs is that because only a small number of residues are involved, the interactions tend to be transient and have low binding affinities. Therefore, they are well suited for mediating functions that require a fast response to changing stimuli, such as interactions between SH2 motifs (which binds a phosphorylated tyrosine) and phosphorylation sites on its binding partners. These three characteristics may provide a flexible molecular basis for fast evolved proteins of RNA viruses with great versatility.

Several pioneering studies were significant for the characterization of SLiMs in viral proteins. Davey et al. collected 52 experimentally validated SLiMs present in viral proteins [@pone.0038637-Davey1]. These examples of viral SLiMs are present in highly studied viral proteins that are responsible for relevant diseases, such as cancers (human papillomavirus, Epstein-Barr virus, human T-cell lymphotropic virus and adenovirus), immunodeficiency (HIV) or the flu (influenza). Currently, a comprehensive SLiM database has been established that is called the Eukaryotic Linear Motif (ELM) Resource for Functional Sites in Proteins [@pone.0038637-Dinkel1]. Based on the motif patterns provided in the ELM database, computational analysis can be performed to identify high potential SLiMs in target proteins and can reduce the arduous and high cost laboratory procedures that are required to identify them.

The ribonucleoprotein (RNP) complex of influenza A virus (IAV), which is composed of the PA, PB1, PB2 and NP proteins, is essential for virus replication in cells. The RNP complex replicates the segments of the RNA virus genome and transcribes its genes [@pone.0038637-Naffakh1]. Moreover, the RNP complex affects the evolution of IAV through its error-prone RNA polymerase, which produces variants of the viral proteins, including the HA, NA and the RNP themselves. Therefore, virus strains that are better adapted to a new host species are created [@pone.0038637-Matrosovich1]. Additionally, the RNP complex represents a promising drug target because its activities are distinct from RNA polymerase found in the host cell [@pone.0038637-NistalVilln1]. However, despite its biomedical importance, the absence of detailed SLiM information of the RNPs has limited our mechanistic understanding of RNP functions and the ability to design better drugs.

The present study sought to gain a deeper understanding of IAV RNP-host interactions that affect RNP activity in human cells. Using a functional proteomics approach, 96 SLiM consensus sequences (regular expressions) from the ELM server [@pone.0038637-Dinkel1] were used to perform a systemic and comprehensive analysis of IAV RNPs. A comparative study of the SLiM composition of RNPs from IAVs from different hosts and highly virulent/pandemic (HP) IAV strains was performed. Several SLiMs, including highly conserved SLiMs, IAV host specific SLiMs and/or HP IAV specific SLiMs, that might affect RNP function were identified. The results of this study not only provide information on the SLiM compositions of IAV RNPs but also provide insights into the signal transduction pathways and protein interaction networks which IAV RNPs might be involved in.

Materials and Methods {#s2}
=====================

Data {#s2a}
----

In total 63,237 sequences from IAV RNPs were retrieved from the NCBI Influenza Database. After checking for completeness by assessing the N-terminus and the length, 52,505 IAV RNP sequences were used in this study. This data set includes 18,952, 29,230 and 4,323 RNP sequences from IAVs from avian, human and mammalian hosts, respectively ([Information S1](#pone.0038637.s001){ref-type="supplementary-material"}). Hosts of the avian and mammalian IAVs are listed in [Information S2](#pone.0038637.s002){ref-type="supplementary-material"}. A set of 845 RNP sequences ([Information S3](#pone.0038637.s003){ref-type="supplementary-material"}) from highly virulent/pandemic (HP) IAVs, including the 1918 H1N1 IAV from the "Spanish Flu", the H2N2 IAV from the 1957 outbreak, the H3N2 IAV from the 1957 outbreak, the H1N1 IAV from the 1977 Russia outbreak, the 2009 H1N1 IAV from the "swine flu", the H5N1 IAV from the 1997 Hong Kong outbreak and the 2004--2008 highly pathogenic H5N1IAVs from Vietnam, Indonesia and Thailand were analysed.

Information regarding the SLiMs was retrieved from the ELM server (the Eukaryotic Linear Motif Resource for Functional Sites in Proteins) [@pone.0038637-Dinkel1]. SLiMs were classified into four types: protease cleavage sites (prefix CLV), protein motif interacting/binding sites (prefix LIG), posttranslational modification sites (prefix MOD) and subcellular targeting signals (prefix TRG) [@pone.0038637-Dinkel1]. In total, 96 SLiMs that are each supported by more than five real sequences were used in this study and are listed in [Information S4](#pone.0038637.s004){ref-type="supplementary-material"}.

Statistical Methods {#s2b}
-------------------

The tests for differences among *k* proportions were performed as follows [@pone.0038637-Zar1]: *i* = 1, 2, ..., *k*. The degree of freedom *ν* = *k*−1.

The log-likelihood ratio tests for independence were performed as follows [@pone.0038637-Zar1]:The degree of freedom *ν* = (*i*−1)(*j*−1).

The Shannon entropy H was introduced by Shannon as a measurement of uncertainty [@pone.0038637-Shannon1]. This method has been applied to measure the diversity of amino acids to identify biologically important amino acids in viral proteins from Papillomavirus [@pone.0038637-Batista1], West Nile virus [@pone.0038637-Koo1], HCV [@pone.0038637-Li1] and IAV [@pone.0038637-Chen1], [@pone.0038637-Chen2], [@pone.0038637-Pan1]. The Shannon diversity index of each SLiM was computed by the formula:

, where *p* is the proportion of each SLiM [@pone.0038637-Zar1].

### Identity Distributions of Pairwise Alignments {#s2b1}

For a given a SLiM, all sequences harbor the SLiM from each host class were used to perform pairwise alignments and to compute the identity of each pair. For example, the SLiM LIG_PTB_Apo_2\_328 was identified in 4777, 4715 and 746 PA sequences from avian, human and mammalian IAVs, respectively. The 11,407,476 identities from (4777×(4777−1)/2) pairwise alignments were computed using PA sequences from avian IAVs. Similarly, the 11,113,255 identities from (4715×(4715−1)/2) pairwise alignments were computed using PA sequences from human IAVs. The 277,885 identities from (746×(746−1)/2) pairwise alignments were computed using PA sequences from mammalian IAVs. Then, the distributions of the three sets of identities were plotted together.

Perl Programming {#s2c}
----------------

The computer programs that were used in this study for data manipulation and pattern (regular expression) match were written by the author using the Perl programming language. The program used for this data analysis is available on request.

Results {#s3}
=======

An overview of the motif-based diversity of IAV RNP sequences {#s3a}
-------------------------------------------------------------

In total, 96 SLiM consensus sequences (regular expressions) were retrieved from the ELM server and were used to analyze the diversity of SLiM compositions for 52,505 IAV RNP sequences ([Information S1](#pone.0038637.s001){ref-type="supplementary-material"}). For each RNP, the occurrence of a SLiM at a position in the RNP is computed by the number of the RNP sequences with the SLiM at a given position divided by total number of the RNP sequences. For example, 7,222 PA protein sequences from human IAVs were used in this study. A SLiM with an occurrence of 1% for the PA protein from human IAVs means that 72 of the 7,222 PA protein sequences from human IAVs have the SLiM at the same position. As shown in [Figure 1A, 1C, 1E and 1G](#pone-0038637-g001){ref-type="fig"}, the identified SLiMs can be divided into the following three categories: an occurrence of greater than 90%, an occurrence between 90--10% and an occurrence of less than 10%. The group of SLiMs with an occurrence of over 90% (highly conserved) may be basic functional motifs for each RNP. A small fraction of the SLiMs with an occurrence between 90--10% forms the second group which represents partially conserved motifs (conserved in a subset of a RNP). SLiMs of this group have higher Shannon diversity indices than those from the other groups for all four RNPs ([Figure 1B, 1D, 1F and 1H](#pone-0038637-g001){ref-type="fig"}). In contrast, most of SLiMs belong to the third group, which occur in less than 10% of the RNP. These results indicate that most SLiMs might be created sporadically by mutations and might be present in specific IAV strains. Together, the combination of occurrences and the Shannon diversity index can be used to distinguish different types of diversity of the SLiM composition. As shown in [Figure 1](#pone-0038637-g001){ref-type="fig"}, the first group of SLiMs has low Shannon diversity index value and high occurrence (greater than 90%), which represents highly conserved motifs (common for all IAVs). The second group of SLiM has high Shannon diversity index value and occurrence of 90--10%, which represents partially conserved motifs. However, the number of SLiMs in this group is few ([Table 1](#pone-0038637-t001){ref-type="table"}). In contrast, the third group of SLiM has both low Shannon diversity index value and low occurrence (less than 10%). The number of SLiMs in this group is plenty ([Figure 1](#pone-0038637-g001){ref-type="fig"} and [Table 1](#pone-0038637-t001){ref-type="table"}). The average numbers of SLiMs per gene (numbers in the brackets beside the raw frequency in [Table 1](#pone-0038637-t001){ref-type="table"}) indicate the second and third SLiM groups represent different types of SLiM composition diversity.

![The distribution of occurrence and the Shannon diversity index of SLiMs in IAV RNPs.\
For A, C, E and G the Y-axis indicates the number of identified SLiMs, and the X-axis indicates the occurrence of the SLiMs. For B, D, F and H the Y-axis indicates the Shannon diversity index. The X-axis indicates the occurrences of SLiMs. The occurrence of a SLiM at an aa position is computed by the number of the RNP sequences with the SLiM at the same position divided by total number of the RNP sequences. (A) The frequency distribution of the identified SLiMs in the PA protein sequences. (B) The Shannon diversity index distribution of the identified SLiMs in the PA protein sequences. (C) The frequency distribution of the identified SLiMs in the PB1 protein sequences. (D) The Shannon diversity index distribution of the identified SLiMs in the PB1 protein sequences. (E) The frequency distribution of the identified SLiMs in the PB2 protein sequences. (F) The Shannon diversity index distribution of the identified SLiMs in the PB2 protein sequences. (G) The frequency distribution of the identified SLiMs in the NP protein sequences. (H) The Shannon diversity index distribution of the identified SLiMs in the NP protein sequences.](pone.0038637.g001){#pone-0038637-g001}
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###### A Comparison of the SLiM distributions of RNPs from highly virulent/pandemic (Pan) IAVs and RNPs from all IAVs. Numbers in the brackets beside the raw frequency are average numbers of SLiMs per gene.

![](pone.0038637.t001){#pone-0038637-t001-1}

  Occurrence      1∼0.9      0.9∼0.1      0.1∼0
  ------------ ----------- ----------- -----------
  All PA        80 (79.3)   24 (12.3)   687 (1.2)
  Pan_PA        80 (79.0)   24 (13.6)   48 (3.3)
  All PB1       80 (79.3)   14 (8.0)    689 (0.9)
  Pan_PB1       80 (79.0)   13 (8.8)    33 (0.7)
  All PB2       94 (93.3)   25 (9.7)    593 (1.2)
  Pan_PB2       94 (92.5)   23 (9.6)    40 (2.2)
  All NP        37 (36.1)   28 (12.5)   565 (0.7)
  Pan_NP        37 (36.9)   25 (11.0)   21 (0.2)

### Comparison of PA protein SLiM compositions among IAVs from different hosts {#s3a1}

To gain a deeper understanding of the SLiM composition of IAV RNPs, the SLiM compositions of IAV RNPs from different hosts were compared. Using the PA protein as an example, the comparison of the SLiM composition of PA proteins among IAVs from avian (A_PA), human (H_PA) and mammalian (M_PA) hosts reveals that the 791 identified SLiMs can be classified into three groups ([Information S5](#pone.0038637.s005){ref-type="supplementary-material"}). The first group is composed of 80 highly conserved SLiMs (with an occurrence of greater than 90% in all PA protein sequences) that are common in all PA proteins regardless of the IAV host range ([Information S6](#pone.0038637.s006){ref-type="supplementary-material"}). The 80 SLiMs may be basic motifs that are essential for normal PA protein functions. The second group includes 24 partially conserved SLiMs (with an occurrence between 90--10% for all PA protein sequences). The third group contains 687 low occurrence SLiMs (with an occurrence of less than 10% in all PA protein sequences). 21 locations that contain two or more overlapping SLiMs from the first group were found (red rectangles in [Information S6](#pone.0038637.s006){ref-type="supplementary-material"}). Locations with highly conserved overlapping SLiMs may represent short protein domains that can respond to multiple host factors/pathways (see [discussion](#s4){ref-type="sec"}).

To uncover IAV host specific motifs in PA proteins in the second group, the test for difference among *k* proportions was performed. Because of the large sample size used in this study, a *p* value of 10^−100^ was used as the cut-off value. In total, 14 SLiMs that have a *p* value of less than 10^−100^ and have an occurrence of greater than 80% in the PA protein sequences from avian, human or mammalian IAVs were identified. Moreover, the log-likelihood ratio tests were performed to test the dependence between the existence of a SLiM and the host origin of the PA protein. All 14 SLiMs have a *p* value of less than 0.05 indicate there are dependences between the existence of the 14 SLiMs and the host origin of PA proteins. As shown in [Figure 2A](#pone-0038637-g002){ref-type="fig"}, all 14 SLiMs have a lower occurrence in PA proteins from human IAVs than in PA proteins from avian and mammalian IAVs. Notably, three of the SLiMs (LIG_SPAK-OSR1_1\_204, MOD_PIKK_1\_274 and MOD_GSK3_1\_402) occur rarely in PA proteins from human IAVs. It is known that the PA sequences are not completely independent because there are phylogenetic relationships between them. A SLiM may be derived either from sequences of the same lineage (founder effect) or from host adaptation (convergent evolution). To reveal the underlying phylogenetic relationship, all PA sequences from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed ([Figure 2B](#pone-0038637-g002){ref-type="fig"}). Moreover, all sequences harbor a SLiM from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed. Two of the 14 SLiMs are shown in [Figure 2C and 2D](#pone-0038637-g002){ref-type="fig"} as examples. If two PA protein sequences with an identity greater than 95% are considered as sequences from the same lineage, then a SLiM identified from PA protein sequences with an identity greater than 95% may represent a result of founder effect. In contrast, a SLiM identified from PA protein sequences with an identity less than 95% may represent an event of host adaptation (convergent evolution). Results in [Figure 2C and 2D](#pone-0038637-g002){ref-type="fig"} suggest both of the founder effect and host adaptation were occurred. Similar phenomena were found for other SLiMs ([Information S7](#pone.0038637.s007){ref-type="supplementary-material"}).

![SLiMs from IAV PA proteins that have a differential occurrence in IAVs from different hosts.\
(A) 14 SLiMs that have a differential occurrence in IAV PA proteins from different hosts. A_PA, H_PA and M_PA indicate the PA proteins from avian, human and IAV, respectively. The Y-axis indicates the occurrence of each identified SLiM. The X-axis indicates the name and position of each identified SLiM in the PA proteins. For example, "LIG_14-3-3_3" in "LIG_14-3-3_3\_615" is the name of the SLiM, and 615 is the amino acid position where the SLiM starts. (B) The distribution of pairwise alignment identity of all PA protein sequences from avian, human and mammalian IAVs. (C) The distribution of pairwise alignment identity of PA protein sequences which harbor the SLiM LIG_PTB_Apo_2\_328 from avian, human and mammalian IAVs. (D) The distribution of pairwise alignment identity of PA protein sequences which harbor the SLiM LIG_SPAK-OSR1_1\_204 from avian, human and mammalian IAVs. For B, C and D, the X-axis indicates the number of pairwise alignments of IAV PA protein sequences. The Y-axis indicates the identity of pairwise alignment (the percentage of identical amino acids that are the same in both PA sequences). Blue: PA protein sequences from avian IAVs. Red: PA protein sequences from human IAVs. Green: PA protein sequences from mammalian IAVs.](pone.0038637.g002){#pone-0038637-g002}

Comparison of the SLiM compositions of PA protein from IAVs with different virulence {#s3b}
------------------------------------------------------------------------------------

To uncover potential IAV virulence-associated motifs in PA proteins, a comparison of PA SLiM compositions from all IAVs and HP IAVs was conducted. The 152 SLiMs identified can be classified into three groups ([Information S8](#pone.0038637.s008){ref-type="supplementary-material"}). The first group is composed of 80 highly conserved SLiMs (with an occurrence of greater than 90% in all PA protein sequences) that are common in all PA proteins regardless of IAV virulence. The second group includes 24 partially conserved SLiMs (with an occurrence between 90--10% in all PA protein sequences). The third group has 48 low occurrence SLiMs (with an occurrence of less than 10% in all PA protein sequences). Therefore, the number of candidate motifs in the third group was reduced from 687 to 48. If a SLiM appears in PA proteins from HP IAVs but is very rare in PA proteins from human IAVs, it may be associated with the virulence of HP IAVs through its effect on the function of the PA protein. Using two criteria, a very low occurrence (less than 10%) in human IAV PA proteins and its presence in HP IAV PA proteins, 47 SLiMs from the second (24 motifs) and third (48 motifs) groups were identified. Moreover, a SLiM from the second group that has a high occurrence in PA proteins from both avian and mammalian IAVs but a low occurrence (19.5%) in PA proteins from human IAVs was found. The 48 SLiMs ([Information S9](#pone.0038637.s009){ref-type="supplementary-material"}) are candidate sites that might affect PA protein activity and might be associated with IAV transcription and/or replication efficiency. 10 of the 48 SLiMs are even more notable. 3 of the 10 SLiMs (LIG_14-3-3_3\_57, MOD_PIKK_1\_650 and MOD_CK2_1\_650) are likely avian IAV specific (labelled "A" in [Information S9](#pone.0038637.s009){ref-type="supplementary-material"}). 4 of the 10 SLiMs (MOD_CK2_1\_17, LIG_FHA_2\_18 and MOD_CK2_1\_686) are likely mammalian IAV specific (labelled "M" in [Information S9](#pone.0038637.s009){ref-type="supplementary-material"}). Another 3 of the 10 SLiMs (LIG_SPAK-OSR1_1\_204, MOD_PIKK_1\_274 and MOD_GSK3_1\_402) have a high occurrence in PA proteins from avian and mammalian IAVs (labelled "A & M" in [Information S9](#pone.0038637.s009){ref-type="supplementary-material"}).

Comparison of the SLiM compositions of PB1 proteins among IAVs from different hosts {#s3c}
-----------------------------------------------------------------------------------

A comparison of PB1 SLiM compositions among IAVs from avian (A_PB1), human (H_PB1) and mammalian (M_PB1) hosts reveals that the 783 identified SLiMs can be classified into three groups ([Information S10](#pone.0038637.s010){ref-type="supplementary-material"}). The first class is composed of 81 highly conserved SLiMs (with an occurrence of greater than 90% in all PB1 protein sequences) that are common in all PB1 proteins regardless of the IAV host range ([Information S11](#pone.0038637.s011){ref-type="supplementary-material"}). These 81 SLiMs may be basic motifs that are essential for normal PB1 protein functions. The second class includes 13 partially conserved SLiMs (with an occurrence between 90--10% in all PB1 protein sequences). The third class has 689 low occurrence SLiMs (with an occurrence of less than 10% in all PB1 protein sequences). 17 locations that contain two or more overlapping SLiMs from the first group were identified (red rectangles in [Information S11](#pone.0038637.s011){ref-type="supplementary-material"}).

To uncover IAV host specific motifs in PB1 proteins in the second group, the test for difference among *k* proportions is performed. Using the *p* value of 10^−100^ as a cut off value, 9 SLiMs were identified that have an occurrence of greater than 80% in the PB1 protein sequences from avian, human or mammalian IAVs. Moreover, the log-likelihood ratio tests were performed to test the dependence between the existence of a SLiM and the host origin of the PB1 protein. All 9 SLiMs have a *p* value of less than 0.05 indicate there are dependences between the existence of the 9 SLiMs and the host origin of PB1 proteins. As shown in [Figure 3A](#pone-0038637-g003){ref-type="fig"}, 8 of the 9 SLiMs have a lower occurrence in PB1 proteins from human IAVs than PB1 proteins from avian and mammalian IAVs. Notably, two of them (LIG_MAPK_1\_584 and MOD_PAK_2\_429) have a very low occurrence in PB1 proteins from human IAVs. In contrast, The SLiM MOD_PIKK_1\_580 is specific to the PB1 proteins from human and mammalian IAVs. To reveal the underlying phylogenetic relationship, all PB1 sequences from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed ([Figure 3B](#pone-0038637-g003){ref-type="fig"}). Moreover, all sequences harbor a SLiM from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed. Two of the 9 SLiMs are shown in [Figure 3C and 3D](#pone-0038637-g003){ref-type="fig"} as examples. If two PB1 protein sequences with an identity greater than 95% are considered as sequences from the same lineage, then a SLiM identified from PB1 protein sequences with an identity greater than 95% may represent a result of founder effect. In contrast, a SLiM identified from PB1 protein sequences with an identity less than 95% may represent an event of host adaptation (convergent evolution). Results in [Figure 3C and 3D](#pone-0038637-g003){ref-type="fig"} suggest both of the founder effect and host adaptation were occurred. Similar phenomena were found for other SLiMs ([Information S12](#pone.0038637.s012){ref-type="supplementary-material"}).

![SLiMs from IAV PB1 proteins that have a differential occurrence in IAVs from different hosts.\
(A) 9 SLiMs that have a differential occurrence in IAV PB1 proteins from different hosts. A_PB1, H_PB1 and M_PB1 indicate the PB1 proteins from avian, human and IAV, respectively. The Y-axis indicates the occurrence of each identified SLiM. The X-axis indicates the name and position of each identified SLiM in the PB1 proteins. For example, "LIG_FHA_2" in "LIG_FHA_2\_55" is the name of the SLiM, and 55 is the amino acid position where the SLiM starts. (B) The distribution of pairwise alignment identity of all PB1 protein sequences from avian, human and mammalian IAVs. (C) The distribution of pairwise alignment identity of PB1 protein sequences which harbor the SLiM LIG_FHA_2\_55 from avian, human and mammalian IAVs. (D) The distribution of pairwise alignment identity of PB1 protein sequences which harbor the SLiM MOD_PKA_2\_429 from avian, human and mammalian IAVs. For B, C and D, the X-axis indicates the number of pairwise alignments of IAV PB1 protein sequences. The Y-axis indicates the identity of pairwise alignment (the percentage of identical amino acids that are the same in both PB1 sequences). Blue: PB1 protein sequences from avian IAVs. Red: PB1 protein sequences from human IAVs. Green: PB1 protein sequences from mammalian IAVs.](pone.0038637.g003){#pone-0038637-g003}

Comparison of the SLiM composition of the PB1 protein from IAVs of different levels of virulence {#s3d}
------------------------------------------------------------------------------------------------

To uncover potential IAV virulence-associated motifs in PB1 proteins, a comparison of PB1 SLiM compositions from all IAVs and HP IAVs was conducted. The 126 SLiMs identified can be classified into three groups ([Information S13](#pone.0038637.s013){ref-type="supplementary-material"}). The first group is composed of 81 highly conserved SLiMs (with an occurrence of greater than 90% in all PB1 protein sequences) that are common in all PB1 proteins regardless of IAV virulence. The second group includes 12 partially conserved SLiMs (with an occurrence between 90--10% in all PB1 protein sequences). The third group has 33 low occurrence SLiMs (with an occurrence of less than 10% of all PB1 protein sequences). Therefore, the number of candidate motifs in the third group was reduced from 689 to 33. If a SLiM appears in PB1 proteins from HP IAVs but is very rare in PB1 proteins from human IAVs, it may be associated with the virulence of HP IAVs through its effect on the function of the PB1 protein. Using two criteria, a very low occurrence (less than 10%) in human IAV PB1 proteins and the presence in HP IAV PB1 proteins, 33 SLiMs from the second and third groups were identified. Moreover, two SLiMs from the second group were found that have a high occurrence in PB1 proteins from avian and mammalian IAVs but a low occurrence (approximately 20%) in PB1 proteins from human IAVs. The 35 SLiMs ([Information S14](#pone.0038637.s014){ref-type="supplementary-material"}) are candidate sites that might affect PB1 protein activity and might be associated with IAV transcription and/or replication efficiency. Notably, 2 of the 35 SLiMs (MOD_PAK_2\_429 and LIG_MAPK_1\_584) are both avian and/or mammalian IAV specific (labelled "A & M" in [Information S14](#pone.0038637.s014){ref-type="supplementary-material"}).

Comparison of the SLiM compositions of PB2 proteins among IAVs from different hosts {#s3e}
-----------------------------------------------------------------------------------

A comparison of PB2 SLiM compositions among IAVs from avian (A_PB2), human (H_PB2) and mammalian (M_PB2) hosts reveals that the 712 identified SLiMs can be classified into three groups ([Information S15](#pone.0038637.s015){ref-type="supplementary-material"}). The first class is composed of 94 highly conserved SLiMs (with an occurrence of greater than 90% of all PB2 protein sequences) that are common in all PB2 proteins regardless of the IAV host range ([Information S16](#pone.0038637.s016){ref-type="supplementary-material"}). The 94 SLiMs may be basic motifs that are essential for normal PB2 protein functions. The second class includes 25 partially conserved SLiMs (with an occurrence between 90--10% of all PB2 protein sequences). The third class has 593 low occurrence SLiMs (with an occurrence of less than 10% of all PB2 protein sequences). In total, 23 locations that contain two or more overlapping SLiMs from the first group were found (red rectangles in [Information S16](#pone.0038637.s016){ref-type="supplementary-material"}).

To uncover IAV host specific motifs in PB2 proteins in the second group, the test for difference among *k* proportions is performed. Using the *p* value of 10^−100^ as a cut-off value, 9 SLiMs that have an occurrence of greater than 80% in PB2 protein sequences from avian, human or mammalian IAVs were identified. Moreover, the log-likelihood ratio tests were performed to test the dependence between the existence of a SLiM and the host origin of the PB2 protein. All 9 SLiMs have a *p* value of less than 0.05 indicate there are dependences between the existence of the 9 SLiMs and the host origin of PB2 proteins. As shown in [Figure 4A](#pone-0038637-g004){ref-type="fig"}, 7 of the 9 SLiMs have lower occurrence in the PB2 proteins from human IAVs than the PB2 proteins from avian and mammalian IAVs. Notably, 3 of the 9 SLiMs (LIG_14-3-3_2\_555, MOD_PAK_1\_268 and MOD_PAK_2\_268) have a very low occurrence in PB2 proteins from human IAVs. In contrast, 2 SLiMs (MOD_CK2_1\_681 and MOD_GSK3_1\_681) are specific to PB2 proteins from human and mammalian IAVs. To reveal the underlying phylogenetic relationship, all PB2 sequences from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed ([Figure 4B](#pone-0038637-g004){ref-type="fig"}). Moreover, all sequences harbor a SLiM from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed. Two of the 9 SLiMs are shown in [Figure 4C and 4D](#pone-0038637-g004){ref-type="fig"} as examples. If two PB2 protein sequences with an identity greater than 95% are considered as sequences from the same lineage, then a SLiM identified from PB2 protein sequences with an identity greater than 95% may represent a result of founder effect. In contrast, a SLiM identified from PB2 protein sequences with an identity less than 95% may represent an event of host adaptation (convergent evolution). Results in [Figure 4C and 4D](#pone-0038637-g004){ref-type="fig"} suggest both of the founder effect and host adaptation were occurred. Similar phenomena were found for other SLiMs ([Information S17](#pone.0038637.s017){ref-type="supplementary-material"}).

![SLiMs from IAV PB2 proteins that have a differential occurrence in IAVs from different hosts.\
(A) 9 SLiMs that have a differential occurrence in IAV PB2 proteins from different hosts. A_PB2, H_PB2 and M_PB2 indicate the PB2 proteins from avian, human and IAV, respectively. The Y-axis indicates the occurrence of each identified SLiM. The X-axis indicates the name and position of each identified SLiM in the PB1 proteins. For example, "LIG_SH3_3" in "LIG_SH3_3\_106" is the name of the SLiM, and 106 is the amino acid position where the SLiM starts. (B) The distribution of pairwise alignment identity of all PB2 protein sequences from avian, human and mammalian IAVs. (C) The distribution of pairwise alignment identity of PB2 protein sequences which harbor the SLiM LIG_SH3_3\_106 from avian, human and mammalian IAVs. (D) The distribution of pairwise alignment identity of PB2 protein sequences which harbor the SLiM MOD_GSK3_1\_681 from avian, human and mammalian IAVs. For B, C and D, the X-axis indicates the number of pairwise alignments of IAV PB2 protein sequences. The Y-axis indicates the identity of pairwise alignment (the percentage of identical amino acids that are the same in both PB2 sequences). Blue: PB2 protein sequences from avian IAVs. Red: PB2 protein sequences from human IAVs. Green: PB2 protein sequences from mammalian IAVs.](pone.0038637.g004){#pone-0038637-g004}

Comparison of the SLiM composition of PB2 proteins from IAVs with different levels of virulence {#s3f}
-----------------------------------------------------------------------------------------------

To uncover potential IAV virulence-associated motifs in PB2 proteins, a comparison of PB2 SLiM compositions from all IAVs and HP IAVs was conducted. The 157 SLiMs identified can be classified into three groups ([Information S18](#pone.0038637.s018){ref-type="supplementary-material"}). The first group is composed of 94 highly conserved SLiMs (with an occurrence of greater than 90% in all PB2 protein sequences) that are common in all PB2 proteins regardless of IAV virulence. The second group includes 23 partially conserved SLiMs (with an occurrence between 90--10% in all PB2 protein sequences). The third group has 40 low occurrence SLiMs (with an occurrence less than 10% in all PB2 protein sequences). Therefore, the number of candidate motifs in the third group was reduced from 593 to 40. If a SLiM appears in the PB1 proteins from HP IAVs but is very rare in PB2 proteins from human IAVs, it may be associated with the virulence of HP IAVs through its effect on the function of the PB2 protein. Using two criteria, a very low occurrence (less than 10%) in human IAV PB2 proteins and the presence in HP IAV PB2 proteins, 41 SLiMs from the second and third groups were identified. Moreover, a SLiM from the second group was found that has a high occurrence in PB2 proteins from avian and mammalian IAVs but a low occurrence (25.4%) in PB2 proteins from human IAVs. The 42 SLiMs ([Information S19](#pone.0038637.s019){ref-type="supplementary-material"}) are candidates sites that might affect PB2 protein activity and might be associated with IAV transcription and/or replication efficiency. Importantly, 14 of the 42 SLiMs are even more notable. Three of them (MOD_CK2_1\_336, LIG_FHA_2\_337 and LIGTRAF2_1\_339) are avian IAV specific (labelled "A" in [Information S19](#pone.0038637.s019){ref-type="supplementary-material"}). Another eight SLiMs (LIG_SH3_3\_536, TRG_LysEnd_APsAcLL_1\_441, MOD_PKA_2\_659, LIG_APCC_KENbox_2\_698, MOD_CK2_1\_714, LIG_FHA_2\_715, TRG_NLS_MonoCore_2\_735 and TRG_NLS_MonoExtN_4\_736) are mammalian IAV specific (labelled "M" in [Information S19](#pone.0038637.s019){ref-type="supplementary-material"}). Three SLiMs (MOD_PKA_1\_268, MOD_PKA_2\_268 and LIG_14-3-3_2\_555) are avian and mammalian IAV specific (labelled "A & M" in [Information S19](#pone.0038637.s019){ref-type="supplementary-material"}).

Comparison of the SLiM composition of NP proteins among IAVs from different hosts {#s3g}
---------------------------------------------------------------------------------

A comparison of NP SLiM compositions among IAVs from avian (A_NP), human (H_NP) and mammalian (M_NP) hosts reveals that the 630 identified SLiMs can be classified into three groups ([Information S20](#pone.0038637.s020){ref-type="supplementary-material"}). The first class is composed of 37 highly conserved SLiMs (with an occurrence of greater than 90% in all NP protein sequences) that are common in all NP proteins regardless of IAV host range ([Information S21](#pone.0038637.s021){ref-type="supplementary-material"}). The 37 SLiMs may be basic motifs that are essential for normal NP protein functions. The second class includes 28 partially conserved SLiMs (with an occurrence between 90--10% in all NP protein sequences). The third class has 565 low occurrence SLiMs (with an occurrence of less than 10% in all NP protein sequences). 6 locations that contain two or more overlapping SLiMs from the first group were found (red rectangles in [Information S21](#pone.0038637.s021){ref-type="supplementary-material"}).

To uncover IAV host specific motifs in NP proteins in the second group, the test for differences among *k* proportions is performed. Using the *p* value of 10^−100^ as a cut-off value, 13 SLiMs that have an occurrence of greater than 80% in the NP protein sequences from avian, human or mammalian IAVs were identified. Moreover, the log-likelihood ratio tests were performed to test the dependence between the existence of a SLiM and the host origin of the NP protein. All 13 SLiMs have a *p* value of less than 0.05 indicate there are dependences between the existence of the 13 SLiMs and the host origin of NP proteins. As shown in [Figure 5A](#pone-0038637-g005){ref-type="fig"}, 10 of the 13 SLiMs have a lower occurrence in the NP proteins from human IAVs than in the NP proteins from avian and mammalian IAVs. Notably, 2 of them (LIG_BRCT_BRCA1_1\_309 and LIG_MAPK_1\_98) have a very low occurrence in NP proteins from human IAVs. In contrast, 2 SLiMs (MOD_SUMO_451 and TRG_ENDOCYTIC_2\_97) are specific to the NP proteins from human and mammalian IAVs. To reveal the underlying phylogenetic relationship, all NP sequences from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed ([Figure 5B](#pone-0038637-g005){ref-type="fig"}). Moreover, all sequences harbor a SLiM from each host class were used to perform pairwise alignments and the identities of all sequence pairs were computed. Two of the 13 SLiMs are shown in [Figure 5C and 5D](#pone-0038637-g005){ref-type="fig"} as examples. If two NP protein sequences with an identity greater than 95% are considered as sequences from the same lineage, then a SLiM identified from NP protein sequences with an identity greater than 95% may represent a result of founder effect. In contrast, a SLiM identified from NP protein sequences with an identity less than 95% may represent an event of host adaptation (convergent evolution). Results in [Figure 5C and 5D](#pone-0038637-g005){ref-type="fig"} suggest both of the founder effect and host adaptation were occurred. Similar phenomena were found for other SLiMs ([Information S22](#pone.0038637.s022){ref-type="supplementary-material"}).

![SLiMs from IAV NP proteins that have a differential occurrence in IAVs from different hosts.\
(A) 13 SLiMs that have a differential occurrence in IAV NP proteins from different hosts. A_NP, H_NP and M_NP indicate the NP proteins from avian, human and IAV, respectively. The Y-axis indicates the occurrence of each identified SLiM. The X-axis indicates the name and position of each identified SLiM in the NP proteins. For example, "MOD_SUMO" in "MOD_SUMO_451" is the name of the SLiM, and 451 is the amino acid position where the SLiM starts. (B) The distribution of pairwise alignment identity of all NP protein sequences from avian, human and mammalian IAVs. (C) The distribution of pairwise alignment identity of NP protein sequences which harbor the SLiM LIG_BRCT_BRCA1_1\_309 from avian, human and mammalian IAVs. (D) The distribution of pairwise alignment identity of NP protein sequences which harbor the SLiM MOD_SUMO_451 from avian, human and mammalian IAVs. For B, C and D, the X-axis indicates the number of pairwise alignments of IAV NP protein sequences. The Y-axis indicates the identity of pairwise alignment (the percentage of identical amino acids that are the same in both NP sequences). Blue: NP protein sequences from avian IAVs. Red: NP protein sequences from human IAVs. Green: NP protein sequences from mammalian IAVs.](pone.0038637.g005){#pone-0038637-g005}

Comparison of the SLiM composition of NP proteins from IAVs with different virulence {#s3h}
------------------------------------------------------------------------------------

To uncover potential IAV virulence associated motifs in NP proteins, a comparison of NP SLiM compositions from all IAVs and HP IAVs was conducted. The 83 SLiMs identified can be classified into three groups ([Information S23](#pone.0038637.s023){ref-type="supplementary-material"}). The first group is composed of 37 highly conserved SLiMs (with an occurrence of greater than 90% in all NP protein sequences) that are common in all NP proteins regardless of IAV virulence. The second group includes 25 partially conserved SLiMs (with an occurrence between 90--10% in all NP protein sequences). The third group has 21 low occurrence SLiMs (with an occurrence of less than 10% in all NP protein sequences). Therefore, the number of candidate motifs in the third group was reduced from 565 to 21. If a SLiM appears in NP proteins from HP IAVs but is very rare in NP proteins from human IAVs, it may be associated with the virulence of the HP IAVs through its effect on the function of the NP protein. Using two criteria, a very low occurrence (less than 10%) in human IAV NP proteins and the presence in HP IAV NP proteins, 24 SLiMs from the second and third groups were identified. The 24 SLiMs ([Information S24](#pone.0038637.s024){ref-type="supplementary-material"}) are candidate sites that might affect NP protein activity and might be associated with IAV transcription and/or replication efficiency. In total, 6 of the 24 SLiMs are even more notable. 3 of them (LIG_APCC_KENbox_2\_318, LIG_14-3-3_3\_470 and MOD_ProDKin_1\_470) are specific to the NP proteins from mammalian IAV (labelled "M" in [Information S24](#pone.0038637.s024){ref-type="supplementary-material"}). Another 3 SLiMs (LIG_MAPK_1\_98, LIG_BRCT_BRCA1_1\_309 and MOD_GSK3_1\_370) are specific to the NP proteins from avian and mammalian IAV (labelled "A & M" in [Information S24](#pone.0038637.s024){ref-type="supplementary-material"}).

SLiMs at the vicinity of amino acids that were associated with host adaptation of IAV PA proteins {#s3i}
-------------------------------------------------------------------------------------------------

Several amino acid sites (AASs) in IAV RNPs were reported to affect IAV RNP activity or were associated with IAV host adaptation [@pone.0038637-AbdelMoneim1]--[@pone.0038637-Yao1]. In total, 99 AASs (25 in the PA protein, 16 in the PB1 protein, 31 in the PB2 protein and 27 in the NP protein) from these reports were mapped to 185 SLiMs (42 in the PA protein, 35 in the PB1 protein, 67 in the PB2 protein and 41 in the NP protein) identified in this study ([Table 2](#pone-0038637-t002){ref-type="table"}--[](#pone-0038637-t003){ref-type="table"} [](#pone-0038637-t004){ref-type="table"} [5](#pone-0038637-t005){ref-type="table"}). For instance, Gabriel et al used the highly pathogenic avian IAV SC35 to demonstrate that 7 AASs in IAV RNPs are associated with host adaptation [@pone.0038637-Gabriel1]. All 7 of the AASs have corresponding SLiMs identified in this study. The AAS 615 of the PA protein can be mapped to LIG_FHA_2\_612, LIG_14-3-3_3\_615 and LIG_14-3-3_1\_615 of the PA protein ([Table 2](#pone-0038637-t002){ref-type="table"}). The AAS 13 of the PB1 protein can be mapped to MOD_PIKK_1\_11 and MOD_GSK3_1\_13 of the PB1 protein ([Table 3](#pone-0038637-t003){ref-type="table"}). The AAS 678 of the PB1 protein can be mapped to MOD_PIKK_1\_675 of the PB1 protein ([Table 3](#pone-0038637-t003){ref-type="table"}). The AAS 333 of the PB2 protein can be mapped to MOD_PKA_1\_331, MOD_PKA_2\_331, MOD_CK2_1\_335, MOD_CK2_1\_336 and LIG_FHA_2\_336 of the PB2 protein ([Table 4](#pone-0038637-t004){ref-type="table"}). The AAS 701 of the PB2 protein can be mapped to LIG_MAPK_1\_702 of the PB2 protein ([Table 4](#pone-0038637-t004){ref-type="table"}). The AAS 714 of the PB2 protein can be mapped to MOD_CK2_1\_714, LIG_FHA_2\_715 and MOD_SUMO_717 of the PB2 protein ([Table 4](#pone-0038637-t004){ref-type="table"}). The AAS 319 of the NP protein can be mapped to LIG_APCC_KENbox_2\_318 and MOD_GSK3_1\_319 of the NP protein ([Table 5](#pone-0038637-t005){ref-type="table"}). Altogether, SLiMs identified in this study provide possible molecular mechanisms that may explain the activity, interaction or localization changes of IAV RNPs caused by those AAS changes.

10.1371/journal.pone.0038637.t002

###### SLiMs mapped to the vicinity of amino acids that were reported as genetic signatures or are associated with the adaptation of IAV PA proteins to the host.

![](pone.0038637.t002){#pone-0038637-t002-2}

  SLiMs identified in this study    Start   End           SLiM sequences             Amino acid                                                              References
  -------------------------------- ------- ----- --------------------------------- --------------- -------------------------------------------------------------------------------------------------------------------------------
  LIG_FHA_2\_18                      18     24         IVELA**EKTMKE**YGEDLK           20, 22                                                [@pone.0038637-Li3], [@pone.0038637-Song1]
  MOD_SUMO_28                        28     31          EYGED**PKIE**TNKFA               28                                 [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_14-3-3_3\_57                   57     62       HFI**D**E**RSESII**VESGD          55, 57                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_14-3-3_2\_57                   57     63       HFI**D**E**RGESTIV**ESGDP         55, 57                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  MOD_GSK3_1\_58                     58     65      FI**D**E**RGESTIVES**GDPNA         55, 57                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  MOD_GSK3_1\_62                     62     69        RGESI**IVESGDPT**ALLKH           65, 66                                             [@pone.0038637-Miotto1], [@pone.0038637-Shinya1]
  LIG_SH3_3\_62                      62     68         QGESI**IVEPEDP**NALLK           65, 66                                             [@pone.0038637-Miotto1], [@pone.0038637-Shinya1]
  TRG_NES_CRM1_1\_67                 67     80     IVE**SGDLNALLKHRFEIIE**GRDRT        65, 66                                             [@pone.0038637-Miotto1], [@pone.0038637-Shinya1]
  LIG_NRBOX_67                       67     73         IVE**SGDLNALLK**HRFEI           65, 66                                             [@pone.0038637-Miotto1], [@pone.0038637-Shinya1]
  MOD_GSK3_1\_82                     82     89        EIIEG**RDRTMAWT**VVNSI             85                                                            [@pone.0038637-Bussey1]
  LIG_PP1_82                         82     89        EIIEG**RDRTIAWT**VINSI             85                                                            [@pone.0038637-Bussey1]
  LIG_FHA_2\_96                      96     102        VNSIC**NTTGVEK**PKFLP           97, 100       [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Song1], [@pone.0038637-Song2]
  LIG_SH3_3\_97                      97     103        NSICN**TTGVEKP**KFLPD           97, 100       [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Song1], [@pone.0038637-Song2]
  LIG_FHA_2\_121                     121    127        RFIEI**GVTRREV**HIYYL             127                                                        [@pone.0038637-AbdelMoneim1]
  LIG_SH2_STAT5_131                  131    134         EVHIY**YLEK**ANKIK               133                                                           [@pone.0038637-Brown1]
  MOD_GSK3_1\_133                    133    140       HIYYL**EKATKIKS**ENTHI             133                                                           [@pone.0038637-Brown1]
  MOD_GSK3_1\_187                    187    194       MASR**GLWDSFRQS**ERGEE             186                                                           [@pone.0038637-Bussey1]
  LIG_SPAK-OSR1_1\_204               204    208         ETIEE**RFEIT**GTMRK              204                                                            [@pone.0038637-Chen3]
  MOD_CK2_1\_221                     221    227        DQSLP**PNFSSLE**NFRAY             225                                [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_CYCLIN_1\_266                  266    270         LKTTP**RPLRL**PNGPP              268                                [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_14-3-3_1\_266                  266    271        LKTTP**RPLTLP**DGPPC              268                                [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_FHA_2\_267                     267    273        KTTPR**PLTLPDG**PPCSQ             268                                [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_SH3_3\_268                     268    274        TTPRP**LRLPEGP**PCSQR             268                                [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  MOD_PIKK_1\_274                    274    280        RLPNG**PPCSQRS**KFLLM             277                                                             [@pone.0038637-Li3]
  LIG_WW_1\_274                      274    277         KLPNG**PPCY**QRSKF               277                                                             [@pone.0038637-Li3]
  LIG_SH3_3\_319                     319    325        FFGWK**EPTVVKP**HEKGI             321                                                           [@pone.0038637-Miotto1]
  LIG_SH2_STAT5_321                  321    324         GWKEP**YIVK**PHEKG               321                                                           [@pone.0038637-Miotto1]
  LIG_SH2_STAT5_334                  334    337         GINPN**YLLA**WKQVL               336                                            [@pone.0038637-AbdelMoneim1], [@pone.0038637-Bussey1]
  LIG_CYCLIN_1\_339                  339    342       YLL**S**W**KQLL**AELQD             337                                            [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_Actin_WH2_2\_353               353    369   FEDEK**KIPRVKNMKKTSPLKWA**LGENM     355, 356                                               [@pone.0038637-Chen3], [@pone.0038637-Li3]
  MOD_GSK3_1\_356                    356    363       EEKI**PRTKTMKKT**SQLKW          355, 356                      [@pone.0038637-Chen3], [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_MAPK_1\_358                    358    366     KI**PK**T**KNMKKTIQL**KWALG       355, 356                      [@pone.0038637-Chen3], [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PKA_2\_384                     384    390      VDF**D**D**CRDTSDL**KQYDS           382                                                           [@pone.0038637-Miotto1]
  LIG_CYCLIN_1\_401                  401    405         DEPE**PRSLAI**WVQNE           400, 404                              [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  MOD_GSK3_1\_402                    402    409     EPE**L**R**SLASWIQS**EFNKA      400, 404, 409                           [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  MOD_CK2_1\_418                     418    424        KACEL**TDSSWIE**LDEIG             421                                                           [@pone.0038637-Miotto1]
  LIG_FHA_2\_419                     419    425        ACELT**DSTWIEL**DEIGE             421                                                           [@pone.0038637-Miotto1]
  LIG_SH3_3\_554                     554    560      LLR**T**A**VGQVSRP**MFLYV        552, 556      [@pone.0038637-Brown1], [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_FHA_2\_612                     612    618        MTKEF**FETKSET**WPIGE             615                                           [@pone.0038637-AbdelMoneim1], [@pone.0038637-Gabriel1]
  LIG_14-3-3_3\_615                  615    620        EFFET**KSETWP**IGESP              615                                           [@pone.0038637-AbdelMoneim1], [@pone.0038637-Gabriel1]
  LIG_14-3-3_1\_615                  615    620        EFFEN**RSETWP**IGESP              615                                           [@pone.0038637-AbdelMoneim1], [@pone.0038637-Gabriel1]

10.1371/journal.pone.0038637.t003

###### SLiMs mapped to the vicinity of amino acids that were reported as genetic signatures or are associated with the adaptation of IAV PB1 proteins to the host.

![](pone.0038637.t003){#pone-0038637-t003-3}

  SLiMs identified in this study    Start   End           SLiM sequences           Amino acid                     References
  -------------------------------- ------- ----- -------------------------------- ------------ -------------------------------------------------
  MOD_PIKK_1\_11                     11     17        TLLF**LKVPTQNA**ISTTF            13       [@pone.0038637-Gabriel1], [@pone.0038637-Song1]
  MOD_GSK3_1\_13                     13     20        LFLKV**PAQSAIST**TFPYT           13                  [@pone.0038637-Gabriel1]
  LIG_14-3-3_2\_52                   52     58        HQYSE**RGKWTIN**TETGA            52                   [@pone.0038637-Tamuri1]
  MOD_PKA_2\_53                      53     59        QYSE**RGRWTTNT**ETGAP            52                   [@pone.0038637-Tamuri1]
  MOD_CK2_1\_54                      54     60      YSE**K**G**KWTTNTE**TGAPQ          52                   [@pone.0038637-Tamuri1]
  MOD_GSK3_1\_54                     54     61      YSE**K**G**KWTTNTET**GAPQL         52                   [@pone.0038637-Tamuri1]
  MOD_CK2_1\_103                     103    109       SHPGI**FENSCLE**TMEVV           103                     [@pone.0038637-Li3]
  MOD_GSK3_1\_103                    103    110       SHPGI**FENSCIET**MEVVQ          103                     [@pone.0038637-Li3]
  TRG_LysEnd_APsAcLL_1\_214          214    219        KQKLN**RKGYLI**RALTL           216                    [@pone.0038637-Chen3]
  LIG_SH2_STAT5_217                  217    220         VNKR**GYLIR**ALTLN            216                    [@pone.0038637-Chen3]
  MOD_PIKK_1\_290                    290    296       VVRKM**MTNSQDT**ELSFT           292                     [@pone.0038637-Li3]
  LIG_APCC_Dbox_1\_315               315    323      NENQN**PRMFLAMIT**YITKN          317                [@pone.0038637-AbdelMoneim1]
  LIG_14-3-3_2\_316                  316    322       ENQNP**RVFLTMI**TYITK           317                [@pone.0038637-AbdelMoneim1]
  LIG_SH2_STAT5_324                  324    327         LAMIT**YITR**NQPEW            327                    [@pone.0038637-Chen3]
  MOD_PIKK_1\_325                    325    331       AMITY**ITRSQPE**WFRNV           327                    [@pone.0038637-Chen3]
  MOD_CK2_1\_325                     325    331       AMITY**ITRSQPE**WFRNV           327                    [@pone.0038637-Chen3]
  LIG_14-3-3_2\_334                  334    340       QPEWF**RNILSIA**PIMFS           336       [@pone.0038637-Chen3], [@pone.0038637-Miotto1]
  LIG_FHA_2\_372                     372    378       QIPAE**MLTSIDL**KYFNE           372                     [@pone.0038637-Li3]
  LIG_SH2_GRB2_380                   380    383         SIDLK**YFNES**TRKK            384                [@pone.0038637-AbdelMoneim1]
  LIG_SH2_STAT5_380                  380    383         SIDLK**YFNES**TRKK            384                [@pone.0038637-AbdelMoneim1]
  MOD_CK2_1\_384                     384    390       KYFNE**STRTKIE**KIRPL           384                [@pone.0038637-AbdelMoneim1]
  LIG_FHA_2\_385                     385    391       YFNE**STRTKIEK**IRPLL           384                [@pone.0038637-AbdelMoneim1]
  LIG_MAPK_1\_386                    386    397   FNE**S**T**RKKIEKIRPLLI**DGTAS      384                [@pone.0038637-AbdelMoneim1]
  MOD_GSK3_1\_517                    517    524       FGVSG**INESADMSI**GVTV          517                   [@pone.0038637-Tamuri1]
  LIG_PTB_Apo_2\_551                 551    558       MALQL**FIKNYRYT**YRCHR          552                [@pone.0038637-AbdelMoneim1]
  LIG_PTB_Phospho_1\_551             551    557       MALQL**FIKNYRY**TYRCH           552                [@pone.0038637-AbdelMoneim1]
  MOD_PKA_2\_555                     555    561     LF**I**KD**YRYTYRC**HRGDT         552                [@pone.0038637-AbdelMoneim1]
  MOD_CK2_1\_575                     575    581       TRRSF**ELKTLWE**QTRSK           578                   [@pone.0038637-Shinya1]
  LIG_FHA_2\_576                     576    582       RRSFE**LKTLWDQ**TQSKA           578                   [@pone.0038637-Shinya1]
  MOD_PIKK_1\_580                    580    586       ELKKL**WDQTQSK**AGLLV           584                   [@pone.0038637-Tamuri1]
  MOD_GSK3_1\_580                    580    587       ELKKL**WDQTQSRT**GLLVS          584                   [@pone.0038637-Tamuri1]
  LIG_MAPK_1\_584                    584    591       LWEQT**RSKAGLLV**SDGGP          584                   [@pone.0038637-Tamuri1]
  MOD_SUMO_611                       611    614         IPEVC**LKWE**LMDED            614                   [@pone.0038637-Shinya1]
  LIG_Clathr_ClatBox_1\_615          615    619        CLKW**ELMDVD**YQGRL            614                   [@pone.0038637-Shinya1]
  MOD_PIKK_1\_675                    675    681       RNRSI**LNTSQRG**ILEDE         677, 678     [@pone.0038637-Li2], [@pone.0038637-Gabriel1]

10.1371/journal.pone.0038637.t004

###### SLiMs mapped to the vicinity of amino acids that were reported as genetic signatures or are associated with the adaptation of IAV PB2 proteins to the host.

![](pone.0038637.t004){#pone-0038637-t004-4}

  SLiMs identified in this study    Start   End          SLiM sequences            Amino acid                                                                                                                                          References
  -------------------------------- ------- ----- ------------------------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  LIG_CYCLIN_1\_8                     8     11         RIKEL**RDLM**SQSRT               9                                                                                                                                       [@pone.0038637-Miotto1]
  MOD_GSK3_1\_9                       9     16       IKELR**DLMSQSRT**REILT             9                                                                                                                                       [@pone.0038637-Miotto1]
  MOD_PIKK_1\_9                       9     15        IKELR**DLMSQSR**TREIL             9                                                                                                                                       [@pone.0038637-Miotto1]
  LIG_PP1_44                         44     50        QEKNP**SLRVKWM**MAMKY            44                                                                                                [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_CK2_1\_63                      63     69        TADKR**IIETIPER**NEQG        63, 64, 70                                                                                   [@pone.0038637-Li2], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Song1], [@pone.0038637-Yao1]
  LIG_FHA_2\_64                      64     70        ADKR**IIETIPER**NEQGQ        63, 64, 70                                                                                   [@pone.0038637-Li2], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Song1], [@pone.0038637-Yao1]
  MOD_GSK3_1\_79                     79     86       GQTLW**SKMSDAGS**DRVMV            81                                                                                                                                       [@pone.0038637-Miotto1]
  MOD_PKA_2\_79                      79     85        GQTLW**SRMSDAG**SDRVM            81                                                                                                                                       [@pone.0038637-Miotto1]
  MOD_PKA_2\_104                     104    110       WNRNG**PRTSAVH**YPKVY            105                                                                                                               [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_SH3_3\_106                     106    112       RNGP**MTSTVHYP**KIYKT         105, 108                                                                                                                          [@pone.0038637-Li3], [@pone.0038637-Tamuri1]
  MOD_CK2_1\_152                     152    158       INPGH**ADLSAKE**AQDVI         153, 156                                                                                                                           [@pone.0038637-Li3], [@pone.0038637-Yao1]
  LIG_SH2_STAT5_195                  195    198        KEELQ**YCKIA**PLMVA             199                                                                                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  TRG_ENDOCYTIC_2\_195               195    198        KEELQ**YCKIA**PLMVA             199                                                                                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_ProDKin_1\_196                 196    202       EELQD**CKISPLM**VAYML            199                                                                                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PKA_1\_268                     268    274       ARNIV**RRATVSA**DPLAS            271                                                                                   [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Foeglein1], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  MOD_PKA_2\_268                     268    274       ARNIV**RRATVSA**DPLAS            271                                                                                   [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Foeglein1], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  MOD_GSK3_1\_317                    317    324      KAAMG**LRISSSFS**FGGFT            318                                                                                                                                    [@pone.0038637-AbdelMoneim1]
  MOD_PKA_2\_317                     317    323       KAAMG**LRISSSF**SFGGF            318                                                                                                                                    [@pone.0038637-AbdelMoneim1]
  LIG_14-3-3_2\_318                  318    324       AAMGL**RISSSLS**FGGFT            318                                                                                                                                    [@pone.0038637-AbdelMoneim1]
  LIG_BRCT_BRCA1_1\_319              319    323        AMGL**RISSSF**SFGGF             318                                                                                                                                    [@pone.0038637-AbdelMoneim1]
  MOD_PKA_1\_331                     331    337     GGFTF**KRTSGSS**V**K**REE       333, 339                                                                                                                         [@pone.0038637-Gabriel1], [@pone.0038637-Yao1]
  MOD_PKA_2\_331                     331    337     GGFTF**KRTSGSS**V**K**REE       333, 339                                                                                                                         [@pone.0038637-Gabriel1], [@pone.0038637-Yao1]
  MOD_CK2_1\_335                     335    341     FKR**T**S**GSSVKRE**EEVLT     333, 339, 341                                                                                                                      [@pone.0038637-Gabriel1], [@pone.0038637-Yao1]
  MOD_CK2_1\_336                     336    342     KR**T**SG**SSVTKEE**EVLTG     333, 339, 341                                                                                                                      [@pone.0038637-Gabriel1], [@pone.0038637-Yao1]
  LIG_FHA_2\_336                     336    342     KR**T**SG**SSTKREE**EVLTG     333, 339, 341                                                                                                                      [@pone.0038637-Gabriel1], [@pone.0038637-Yao1]
  MOD_CK2_1\_352                     352    358       GNLQT**LKLTVHE**GYEEF            355                                                                                                                                    [@pone.0038637-AbdelMoneim1]
  LIG_FHA_2\_353                     353    359       NLQTL**KLTVHEG**YEEFT            355                                                                                                                                    [@pone.0038637-AbdelMoneim1]
  MOD_PKA_2\_368                     368    374       FTMVG**RRATAIL**RKATR            368                                                                                                                                      [@pone.0038637-Miotto1]
  MOD_PKA_1\_368                     368    374       FTMVG**RRATAIL**RKATR            368                                                                                                                                      [@pone.0038637-Miotto1]
  LIG_MAPK_1\_476                    476    485     TEMS**MRGIRVSKMGV**DEYSS           475                                                                                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_CYCLIN_1\_476                  476    480        TEMS**MRGLRV**SKMGV             475                                                                                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_FHA_2\_481                     481    487       RGVRV**SKTGVDE**YSSTE            482                                                                                                                                        [@pone.0038637-Yao1]
  TRG_NES_CRM1_1\_492                492    506   EYSST**ERIVVSIDRFLRVRD**QRGNV        493                                                                                                                                      [@pone.0038637-Tamuri1]
  LIG_14-3-3_2\_493                  493    499       YSSTE**RVVVSID**RFLRV            493                                                                                                                                      [@pone.0038637-Tamuri1]
  MOD_ProDKin_1\_530                 530    536       ERLT**ITYSSPMM**WEING         529, 530                                                                                                                                  [@pone.0038637-AbdelMoneim1]
  LIG_PP1_559                        559    565     IRNWE**AVKIQWS**Q**N**PAM          567                                                                                                 [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Yao1]
  MOD_GSK3_1\_562                    562    569      WETVK**IQWSQDPTM**LYNK       567, 569, 570                                                                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  MOD_PIKK_1\_562                    562    568     WETVK**IQWSQDP**T**M**LYN     567, 569, 570                                                                               [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  MOD_PIKK_1\_587                    587    593       SLVPK**AIRSQYS**GFVRT         588, 591                                                                                 [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Foeglein1], [@pone.0038637-Mok1], [@pone.0038637-Miotto1]
  MOD_PKA_2\_590                     590    596     PKA**T**R**SRYSGFV**RTLFQ       588, 591                                                                                 [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Foeglein1], [@pone.0038637-Mok1], [@pone.0038637-Miotto1]
  MOD_PIKK_1\_610                    610    616       DVLGT**FDTTQII**KLLPF         611, 613                                                                                                 [@pone.0038637-Chen3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  MOD_GSK3_1\_659                    659    666      SPVFNY**NKATKRLT**VLGKD           661                                                                                                                          [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PIKK_1\_659                    659    665       PVFNY**NKATQRL**TVLGK            661                                                                                                                          [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PKA_2\_659                     659    665       PVFNY**NRATKRL**TVLGK            661                                                                                                                          [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_CYCLIN_1\_663                  663    667      YNK**A**T**KRLTV**LGKDA           661                                                                                                                          [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PKA_1\_663                     663    669     YNK**A**T**KRLTVLG**KDAGA          661                                                                                                                          [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PKA_2\_663                     663    669     YNK**A**T**KRLTVLG**KDAGA          661                                                                                                                          [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_CK2_1\_671                     671    677       TILGK**DAGTLIE**DPDES            674                                                                                                                       [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  TRG_LysEnd_APsAcLL_1\_671          671    676       TILGK**DAGTLI**EDPDE             674                                                                                                                       [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_FHA_2\_672                     672    678       VLGKD**AGTLTED**PDEGT            674                                                                                                                       [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  MOD_CK2_1\_681                     681    687       IEDP**DESTSGVE**SAVLR       680, 682, 684                                                                                                           [@pone.0038637-Chen3], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  MOD_GSK3_1\_681                    681    688      TEDP**DEGTSGVES**AVLRG       680, 682, 684                                                                                                           [@pone.0038637-Chen3], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  LIG_FHA_2\_682                     682    688     EDP**D**E**GTTGVES**AVLRE     680 682, 684                                                                                                            [@pone.0038637-Chen3], [@pone.0038637-Tamuri1], [@pone.0038637-Yao1]
  LIG_APCC_KENbox_2\_698             698    702        GFLIL**GKENK**RYGPA        698, 701, 702   [@pone.0038637-AbdelMoneim1], [@pone.0038637-Brown1], [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Foeglein1], [@pone.0038637-Gabriel1], [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1], [@pone.0038637-Yamada1], [@pone.0038637-Yao1]
  LIG_MAPK_1\_702                    702    710      LGKE**DKRYGPALSI**NELSN        701, 702      [@pone.0038637-AbdelMoneim1], [@pone.0038637-Brown1], [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Foeglein1], [@pone.0038637-Gabriel1], [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1], [@pone.0038637-Yamada1], [@pone.0038637-Yao1]
  MOD_CK2_1\_714                     714    720       SINEL**SNLTKGE**KANVL            714                                                                                                                                      [@pone.0038637-Gabriel1]
  LIG_FHA_2\_715                     715    721       INEL**SNLTKGEK**ANVLI            714                                                                                                                                      [@pone.0038637-Gabriel1]
  MOD_SUMO_717                       717    720      EL**S**NL**AKGE**KANVL            714                                                                                                                                      [@pone.0038637-Gabriel1]
  MOD_GSK3_1\_738                    738    745      LVMKR**KRDSSILT**DSQTA            740                                                                                                                                      [@pone.0038637-Tamuri1]
  MOD_PKA_2\_738                     738    744      LVMKR**KRDSSIL**TDSQTA            740                                                                                                                                      [@pone.0038637-Tamuri1]
  MOD_PKA_1\_738                     738    744       LVMKR**KRDSSIL**TDSQT            740                                                                                                                                      [@pone.0038637-Tamuri1]
  MOD_GSK3_1\_742                    742    749    RKR**D**S**SILTDSQT**ATKRI          740                                                                                                                                      [@pone.0038637-Tamuri1]

10.1371/journal.pone.0038637.t005

###### SLiMs mapped to the vicinity of amino acids that were reported as genetic signatures or are associated with the adaptation of IAV NP proteins to the host.
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  SLiMs identified in this study    Start   End              SLiM sequences               Amino acid                                                  References
  -------------------------------- ------- ----- -------------------------------------- --------------- -------------------------------------------------------------------------------------------------------
  TRG_ENDOCYTIC_2\_10                10     13             GTKR**SYEQM**ETGGE                  9                                                  [@pone.0038637-Li3]
  MOD_CK2_1\_12                      12     18         KR**S**YE**QMETGGE**RQDAT             9, 16         [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Li3], [@pone.0038637-Miotto1]
  MOD_PKA_2\_18                      18     24         MET**D**G**ERQTATE**IRASV              16                     [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_SH2_STAT5_78                   78     81             ERRN**KYLEE**HPSAG                 77                                                [@pone.0038637-Tamuri1]
  LIG_MAPK_1\_98                     98     110       GGPIY**RRRDGKWMRELIL**YDKEE             100                                   [@pone.0038637-Chen3], [@pone.0038637-Miotto1]
  LIG_Actin_WH2_2\_101               101    119    IYRR**VDGKWMRELILYDKEELRRV**WRQAN     100, 101, 102                  [@pone.0038637-Chen3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_MAPK_1\_102                    102    110         YKR**VDRKWMRELVL**YDKEE          100, 101, 102                  [@pone.0038637-Chen3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_CYCLIN_1\_106                  106    110           DGKWM**RELIL**YDKEE                 109                                                [@pone.0038637-Chen3]
  MOD_GSK3_1\_127                    127    134          QANNG**EDATAGLT**HIMIW               131                                               [@pone.0038637-Tamuri1]
  MOD_PKA_2\_212                     212    218          WRGEN**GRRTRIA**YERMC                214                                   [@pone.0038637-Chen3], [@pone.0038637-Miotto1]
  MOD_CK2_1\_214                     214    220          GENGR**KTRSAYE**RMCNI                214                                   [@pone.0038637-Chen3], [@pone.0038637-Miotto1]
  MOD_CK2_1\_284                     284    290          RESR**NPGNTEIE**DLIFL                283        [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_14-3-3_2\_292                  292    298          GHDF**EREGYSLV**GIDPF             291, 293                                   [@pone.0038637-Chen3], [@pone.0038637-Li3]
  LIG_AP2alpha_2\_302                302    304            SLVGI**DPFK**LLQN                  305        [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PIKK_1\_307                    307    313        DPF**R**L**LQNSQVF**SLIRS              305        [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_GSK3_1\_307                    307    314        DPF**R**L**LQNSQVFS**LIRSN             305        [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  TRG_ENDOCYTIC_2\_313               313    316            QNSQV**YSLI**RPNEN                 313                    [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1]
  LIG_APCC_KENbox_2\_318             318    322           YSLIR**PKENP**AHKSQ                 319                                              [@pone.0038637-Gabriel1]
  MOD_GSK3_1\_319                    319    326          SLIRP**KENSAHKS**QLVWM               319                                              [@pone.0038637-Gabriel1]
  LIG_BRCT_BRCA1_1\_334              334    338           VWMAC**HSAAF**EDLRV                 335                                               [@pone.0038637-Tamuri1]
  LIG_14-3-3_3\_334                  334    339           VWMAC**HSASFE**DLRVS                335                                               [@pone.0038637-Tamuri1]
  LIG_FHA_2\_335                     335    341          WMACH**SATFEDL**RVSSF                335                                               [@pone.0038637-Tamuri1]
  MOD_ProDKin_1\_350                 350    356          SFIRG**TKVSPRG**KLSTR                353                                    [@pone.0038637-Li3], [@pone.0038637-Tamuri1]
  LIG_CYCLIN_1\_351                  351    354            FIRGT**RVLP**RGKLS                 353                                    [@pone.0038637-Li3], [@pone.0038637-Tamuri1]
  MOD_PKA_2\_356                     356    362          KVSPR**GRLSTRG**VQIAS                357        [@pone.0038637-Chen3], [@pone.0038637-Finkelstein1], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_Actin_WH2_2\_367               367    384   GVQ**I**A**SNENMDNMGSGTLELRSG**YWAIR        365                                                 [@pone.0038637-Li3]
  MOD_GSK3_1\_370                    370    377          IASNE**NMETMDSS**TLELR          372, 375, 377       [@pone.0038637-Chen3], [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_CK2_1\_374                     374    380        ENM**D**N**MGSSTLE**LRSGY         372, 375, 377       [@pone.0038637-Chen3], [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  LIG_FHA_2\_375                     375    381          NVEAM**DSTTLEL**RSRYW             375, 377                      [@pone.0038637-Li3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_PKA_2\_421                     421    427          RSLPF**ERATIMA**AFTGN           422, 423, 425                  [@pone.0038637-Chen3], [@pone.0038637-Miotto1], [@pone.0038637-Tamuri1]
  MOD_GSK3_1\_450                    450    457          IRMME**GAKTEEVS**FRGRG            450, 455                                   [@pone.0038637-Chen3], [@pone.0038637-Li3]
  LIG_TRAF6_451                      451    459         RMME**GAKPEEVSFQ**GRGVF            450, 455                                   [@pone.0038637-Chen3], [@pone.0038637-Li3]
  MOD_SUMO_451                       451    454            RMME**GAKPEE**VSFQ              450, 455                                   [@pone.0038637-Chen3], [@pone.0038637-Li3]
  LIG_CtBP_453                       453    457           MESAK**PEDLS**FQGRG                 455                                                [@pone.0038637-Chen3]
  LIG_14-3-3_3\_470                  470    475           ELSDE**KATSPI**VPSFD                472                                               [@pone.0038637-Tamuri1]
  MOD_ProDKin_1\_470                 470    476          ELSDE**KATSPIV**PSFDM                472                                               [@pone.0038637-Tamuri1]
  LIG_SH3_3\_471                     471    477          LSDEK**ATNPIVP**SFDMS                472                                               [@pone.0038637-Tamuri1]

Proposed cellular processes RNPs may be involved through SLiMs identified {#s3j}
-------------------------------------------------------------------------

The compositions of SLiMs in RNPs provide information regarding the pathways that the RNPs may be involved in. As shown in [Table 6](#pone-0038637-t006){ref-type="table"}, RNPs with SH2 and SH3 ligand motifs, LIG_MAPK_1, LIG_14-3-3, LIG_FHA_2 and protein kinase phosphorylation sites may be involved in the MAPK, Wnt and PI3K/AKT/FOXO signal transduction pathways. RNPs with LIG_TRAF2_1, LIG_TRAF6, LIG_SH2_STAT3 and LIG_SH2_STAT5 may be involved in the TNF/cytokine signaling pathway [@pone.0038637-Dinkel1]. Moreover, RNPs with TRG_LysEnd_APsAcLL_1, TRG_ENDOCYTIC_2, LIG_EH1_1 and LIG_Actin_WH2_2 may interact with actin and be involved in intracellular trafficking pathways [@pone.0038637-Dinkel1]. All of these host cellular processes and pathways have been reported to be involved in post-entry steps of IAV replication [@pone.0038637-Shapira1], [@pone.0038637-Knig1]. The different compositions of SLiMs among RNPs reflect the functional diversity of RNPs. Each RNP with a different SLiM composition has a varying ability to interact with different cellular processes and signal transduction pathways, and results in different impacts on viral replication and host adaptation.

10.1371/journal.pone.0038637.t006

###### Functions of SLiMs identified in IAV RNPs. In the ELM database [@pone.0038637-Dinkel1], SLiMs are divided into four types: protease cleavage sites (prefix CLV), protein motif interacting/binding sites (prefix LIG), posttranslational modification sites (prefix MOD) and subcellular targeting signals (prefix TRG).
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  ELM Identifier                                      Description                                 GO_ID                                 GO_Process                                    RNPs
  ---------------------- --------------------------------------------------------------------- ------------ ------------------------------------------------------------------ ------------------
  CLV_PCSK_FUR_1                                The furin cleavage site                         GO:0006508                     Proteolysis And Peptidolysis                           PB1
  LIG_14-3-3_1                           The 14-3-3 protein interacting motif                   GO:0007243                        Protein Kinase Cascade                            PA, PB2
  LIG_14-3-3_2                           The 14-3-3 protein interacting motif                   GO:0007243                        Protein Kinase Cascade                        PA, PB1, PB2, NP
  LIG_14-3-3_3                           The 14-3-3 protein interacting motif                   GO:0007243                        Protein Kinase Cascade                        PA, PB1, PB2, NP
  LIG_Actin_WH2_2                             The actin interacting motif                       GO:0008064        Regulation Of Actin Polymerization Or Depolymerization          PA, PB2, NP
  LIG_AGCK_PIF_1                            The PIF motif interacting motif                     GO:0007165                         Signal Transduction                                PB2
  LIG_AP2alpha_2                           The AP2 complex interacting motif                    GO:0006897                             Endocytosis                                   PA, NP
  LIG_APCC_Dbox_1                         The APC/C complex interacting motif                   GO:0043161      Proteasomal Ubiquitin-Dependent Protein Catabolic Process         PA, PB1, PB2
  LIG_APCC_KENbox_2                       The APC/C complex interacting motif                   GO:0043161      Proteasomal Ubiquitin-Dependent Protein Catabolic Process         PA, PB2, NP
  LIG_BRCT_BRCA1_1                         The BRCT domain interacting motif                    GO:0000077                        Dna Damage Checkpoint                         PA, PB1, PB2, NP
  LIG_Clathr_ClatBox_1         The N-terminus of Clathrin heavy chain interacting motif         GO:0006897                             Endocytosis                                     NP
  LIG_CtBP                                The CtBP protein interacting motif                    GO:0045449                     Regulation Of Transcription                           PA, NP
  LIG_CYCLIN_1                                 Cyclin interacting motif                         GO:0007049                              Cell Cycle                              PA, PB1, PB2, NP
  LIG_EH_1                                    EH domain interacting motif                       GO:0006897                             Endocytosis                                    PB1
  LIG_FHA_2                                  FHA domain interacting motif                       GO:0045449                     Regulation Of Transcription                      PA, PB1, PB2, NP
  LIG_HCF-1_HBM_1                      the Host Cell Factor-1 interacting motif                 GO:0045449                     Regulation Of Transcription                            PB2
  LIG_HP1_1                                  HP1 protein interacting motif                      GO:0006343              Establishment Of Heterochromatin Silencing                  PA, PB2
  LIG_MAD2                                      Mad2 interacting motif                          GO:0007094                      Mitotic Spindle Checkpoint                            PB2
  LIG_MAPK_1                                    MAPK interacting motif                          GO:0007243                        Protein Kinase Cascade                        PA, PB1, PB2, NP
  LIG_NRBOX                               Nuclear receptor interacting motif                    GO:0045449                     Regulation of Transcription                             PA
  LIG_PDZ_Class_2                      The C-terminal class 2 PDZ-binding motif                 GO:0007165                         Signal Transduction                                 NP
  LIG_PP1                    The Protein phosphatase 1 catalytic subunit interacting motif      GO:0007165                         Signal Transduction                            PA, PB1, PB2
  LIG_PTB_Apo_2                        The Dab-like PTB domain interacting motif                GO:0007169   Transmembrane Receptor Protein Tyrosine Kinase Signalimg Pathway       PA, PB1
  LIG_PTB_Phospho_1             The Shc-like and IRS-like PTB domain interacting motif          GO:0007169   Transmembrane Receptor Protein Tyrosine Kinase Signalimg Pathway       PA, PB1
  LIG_RGD                                     The RGD motif binding motif                       GO:0007155                            Cell-Adhesion                               PB1, PB2, NP
  LIG_SH2_GRB2                  The GRB2-like Src Homology 2 (SH2) domain binding motif         GO:0007165                         Signal Transduction                            PA, PB1, PB2
  LIG_SH2_SRC                  The Src-family Src Homology 2 (SH2) domains binding motif        GO:0007165                         Signal Transduction                              PA, PB2
  LIG_SH2_STAT3                         The STAT3 SH2 domain interacting motif                  GO:0045449                     Regulation Of Transcription                            PB1
  LIG_SH2_STAT5                           The STAT5 SH2 domain binding motif                    GO:0045449                     Regulation Of Transcription                      PA, PB1, PB2, NP
  LIG_SH3_3                                The SH3 domain interacting motif                     GO:0007165                         Signal Transduction                          PA, PB1, PB2, NP
  LIG_SPAK-OSR1_1                           SPAK/OSR1 kinase binding motif                      GO:0006468                  Protein Amino Acid Phosphorylation                       PA, NP
  LIG_SxIP_EBH_1                           The EBH domain interacting motif                     GO:0031535                Plus-End Directed Microtubule Sliding                     PB1, NP
  LIG_TRAF2_1                                     TRAF2 binding motif                           GO:0007165                         Signal Transduction                          PA, PB1, PB2, NP
  LIG_TRAF6                                       TRAF6 binding motif                           GO:0007165                         Signal Transduction                            PB1, PB2, NP
  MOD_CDK_1                                    CDK phosphorylation site                         GO:0000308   Cycloplasmic Cyclin-Dependent Protein Kinase Holoenzyme Complex           PA
  MOD_CK2_1                                    CK2 phosphorylation site                         GO:0016055                    Wnt Receptor Signaling Pathway                    PA, PB1, PB2, NP
  MOD_GSK3_1                                   GSK3 phosphorylation site                        GO:0006468                  Protein Amino Acid Phosphorylation                  PA, PB1, PB2, NP
  MOD_PIKK_1                                   PIKK phosphorylation site                        GO:0000077                        Dna Damage Checkpoint                         PA, PB1, PB2, NP
  MOD_PKA_1                            PKA-type AGC kinase phosphorylation site                 GO:0010737                  Protein Kinase A Signaling Cascade                    PA, PB1, PB2
  MOD_PKA_2                            PKA-type AGC kinase phosphorylation site                 GO:0010737                  Protein Kinase A Signaling Cascade                  PA, PB1, PB2, NP
  MOD_ProDKin_1                      Proline-Directed Kinase phosphorylation site               GO:0007165                         Signal Transduction                          PA, PB1, PB2, NP
  MOD_SUMO                                 Motif for modification by SUMO-1                     GO:0016927                             Sumoylation                              PA, PB1, PB2, NP
  MOD_TYR_ITSM                        immunoreceptor tyrosine based switch motif                GO:0006468                  Protein Amino Acid Phosphorylation                        PB2
  TRG_ENDOCYTIC_2           Tyrosine-based sorting signal interacts with adaptor complexes      GO:0006897                             Endocytosis                              PA, PB1, PB2, NP
  TRG_LysEnd_APsAcLL_1    Sorting and internalisation signal interacts with adaptor complexes   GO:0006886                   Intracellular Protein Transport                    PA, PB1, PB2, NP
  TRG_NES_CRM1_1           Nuclear export signal (NES) binding to the CRM1 exportin protein     GO:0051168                            Nuclear Export                              PA, PB2, NP
  TRG_NLS_Bipartite_1                    Bipartite nuclear localization signal                  GO:0006606                        Protein-Nucleus Import                          PB1, PB2, NP
  TRG_NLS_MonoCore_2           Monopartite nuclear localization signal, Strong core type        GO:0006607              Nls-Bearing Substrate Import Into Nucleus                 PA, PB1, PB2
  TRG_NLS_MonoExtC_3           Monopartite nuclear localization signal, C-extended type         GO:0006607              Nls-Bearing Substrate Import Into Nucleus                     PB1
  TRG_NLS_MonoExtN_4           Monopartite nuclear localization signal, N-extended type         GO:0006607              Nls-Bearing Substrate Import Into Nucleus                   PB1, PB2

Discussion {#s4}
==========

In total, 292 highly conserved SLiMs were found in IAV RNPs regardless of IAV host range. These SLiMs may be basic motifs that are essential for the normal function of RNPs. Two of them have been experimentally identified in IAV RNP proteins. The first SLiM is the nuclear localization signal (NLS) located between amino acid 182--217 in the IAV PB1 proteins [@pone.0038637-Hutchinson1]. Several NLS associated SLiMs were identified in this study as shown in [Information S11](#pone.0038637.s011){ref-type="supplementary-material"}. The second SLiM is the nuclear localization signal (NLS) located in the C-terminal of the IAV PB2 proteins [@pone.0038637-Tarendeau1]. The NLS associated SLiM was identified in this study as shown in Information 16. These examples suggest that computational prediction of SLiM is helpful for identification of important function motifs in viral proteins.

In total, 67 locations with overlapping SLiMs were identified among the 292 highly conserved SLiMs in RNPs (red rectangles in [Information S6](#pone.0038637.s006){ref-type="supplementary-material"}, [S11](#pone.0038637.s011){ref-type="supplementary-material"}, [S16](#pone.0038637.s016){ref-type="supplementary-material"}, [S21](#pone.0038637.s021){ref-type="supplementary-material"}). These overlapping SLiMs may act together through three mechanisms. First, multiple SLiM interactions may be used cooperatively to increase the specificity and strength with which two proteins bind to each other. Second, multiple SLiMs may enable interaction between different cellular signals sequentially. For example, the function of the first SLiM may lead to the action of the second SLiM. Third, multiple SLiMs may also enable the interaction between different cellular signals competitively. A protein may contain different SLiMs that target the same amino acid residue for different post translational modifications as inputs from different cellular signals. This could lead to competition (i.e. an interaction) between the two signals, with different enzymes competing to modify the same residue. The different post translational modification states of the motif could bind to different interaction domains and result in different output signals from the interaction.

The SLiMs which have a very low occurrence in RNPs from human IAVs but present in RNPs from HP IAVs could be candidates for novel virulent determinants that are worthy to be further investigated. For example, 10 SLiMs (LIG_SPAK-OSR1_1\_204, MOD_PIKK_1\_274 and MOD_GSK3_1\_402 in PA proteins; MOD_PAK_2\_429 and LIG_MAPK_1\_584 in PB1 proteins; MOD_PKA_1\_268, MOD_PKA_2\_268 and LIG_14-3-3_2\_555 in PB2 proteins; and LIG_MAPK_1\_98 and LIG_BRCT_BRCA1_1\_309 in NP proteins) have a very low occurrence in RNPs from human IAVs but have a high occurrence in RNPs from avian and mammalian IAVs. Moreover, all 10 of the SLiMs were found in RNPs from HP IAVs ([Information S9](#pone.0038637.s009){ref-type="supplementary-material"}, [S14](#pone.0038637.s014){ref-type="supplementary-material"}, [S19](#pone.0038637.s019){ref-type="supplementary-material"}, [S24](#pone.0038637.s024){ref-type="supplementary-material"}). Therefore, they may represent emerging SLiMs in RNPs of avian IAV origin which are in the early stage of adaptation to human hosts. Another type of SLiMs that have a low occurrence in RNPs from avian, human and mammalian IAVs but are present in HP IAVs may also be potential virulent determinants that occurred by coincidence ([Information S9](#pone.0038637.s009){ref-type="supplementary-material"}, [S14](#pone.0038637.s014){ref-type="supplementary-material"}, [S19](#pone.0038637.s019){ref-type="supplementary-material"}, [S24](#pone.0038637.s024){ref-type="supplementary-material"}).

Many proteins are regulated by post-translational modifications (PTMs) that may mediate allosteric effects or create binding sites important for protein-protein interactions where ligand domains can bind to phosphorylated, methylated or sumoylated sites. As described for the ELM server, SLiMs can be classified into four types of functional sites: ligand sites (LIG), PTM sites (MOD), proteolytic cleavage and processing sites (CLV), and sites for subcellular targeting (TRG) [@pone.0038637-Dinkel1]. These functional assignments are useful in that they encompass the range of peptide motif activities. Furthermore, they can also help explain why many amino acid sites have been experimentally demonstrated to be functionally important for RNPs but do not have corresponding SLiMs in this study. For example, the glutamic acid at PB2 position 627 is generally found in avian viruses, whereas nearly all human isolates carry a lysine at this position [@pone.0038637-Subbarao1]. Available data suggests that PB2 position 627 determines the temperature sensitivity of vRNA replication [@pone.0038637-Massin1]. Viruses with PB2 627K can efficiently replicate in the mammalian upper respiratory tract, whereas those that possess PB2 627E cannot [@pone.0038637-Hatta1]. A PB2 E627K mutation enhances avian virus replication in mammalian cells at 33°C, but not at 37°C or 41°C, in vitro [@pone.0038637-Massin1]. A lack of a corresponding SLiM suggests the cold sensitivity of avian virus polymerases with PB2 627E may be because the global domain conformation changes in the PB2 protein are directly affected by the residue itself rather than mediated by a gain or loss of a post-translational modification target site (SLiM).

To validate the putative SLiMs identified in this study several experimental methods can be used. The first method is the reverse genetics technology that is generally used for validation of IAV protein function/activity affected by different amino acid mutations [@pone.0038637-Wang1], [@pone.0038637-Liu1]. The reverse genetics can be coupled with different function assays. For example, to validate the influence of a SLiM in virulence, virus particles produced by reverse genetics can be used to infect model animals (mouse, ferret, swine or primate). The survival rate, pathological changes, cytokine levels in blood could be measured [@pone.0038637-Dankar1], [@pone.0038637-Forbes1]. Interactions between IAV RNPs and known host factors through SLiMs (e.g. LIG_SH2_STAT5 and LIG_TRAF2) identified in this study can be validated by biomolecular fluorescence complementation (BiFC) [@pone.0038637-Hemerka1], [@pone.0038637-Suzuki1] and split luciferase complementation assay (SLCA) [@pone.0038637-Deng1]. Localization of RNPs mediated by targeting signal SLiMs such as nuclear export signal and nuclear localization signal can be validated by fluorescence recovery after photobleaching (FRAP) [@pone.0038637-Foeglein2]. Specific modification such as sumoylation can be validated by immunoblot of SUMO specific antibody [@pone.0038637-Tatham1], [@pone.0038637-Sarge1].

Using protein-protein interactions as targets for antiviral chemotherapy has been proposed over a decade [@pone.0038637-Loregian1]. Currently, this idea is considered in development of antiviral drugs for flaviviruses and HIV [@pone.0038637-Geiss1], [@pone.0038637-Zhan1]. To interfere in protein-protein interactions, using peptides that mimic the interaction motifs is one of the most straightforward approaches [@pone.0038637-Elsawy1]. Several reports demonstrated that peptide-mediated interference in IAV polymerase complex assembly can attenuate IAV replication [@pone.0038637-Muratore1]--[@pone.0038637-Ghanem1]. SLiMs such as PDZ motif [@pone.0038637-Wang2], LIG_SH2_GRB2 [@pone.0038637-Jiang1] are being explored as drug targets. Since viruses have evolved to use motifs for essential functions by hijacking host proteins [@pone.0038637-Kadaveru1], identification of SLiMs which mediate interactions between viral protein and host factors may provide valuable and specific information for development of motif mimetic drugs to perturb the interactions to treat virus infections [@pone.0038637-Davey1].

Inhibition of interactions between viral proteins has the advantage of high specificity and low side effect. However, resistant strains may appear from fast co-evolution of RNA virus proteins under selection pressures. The possibility of co-evolution of RNA virus proteins and mammalian host proteins, on the other hand, is expected to be extremely low. Another concern is that the inability of a synthetic peptide to penetrate cells precluded it from therapeutic usefulness. Nevertheless, discovery of peptidomimetic compounds can be pursued based on the structure of the effective peptide.

In this study, the compositions of SLiMs (target sites of post-translational modifications) of IAV RNPs were analyzed. Three groups of SLiMs with different occurrences for each RNP were found. The SLiMs identified in this study provide an invaluable resource for experimental virologists to study the interactions between IAV RNPs and host intracellular proteins. Moreover, the SLiM compositions of IAV RNPs also provide insights into the signal transduction pathways and protein interaction networks with which IAV RNPs might be involved or interfere. The information of SLiM mediated virus-host protein interactions might be helpful for the development of anti-IAV drugs.
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